28/05/2026
GLP-1 medications like semaglutide and tirzepatide have transformed how we treat type 2 diabetes – but are they supporting long-term metabolic health?
In his latest article, Dr Konrad Grosser explores what GLP-1 medications actually do, what they don't do, and why addressing the underlying drivers of metabolic dysfunction – insulin resistance, inflammation, gut health and body composition – is what turns weight loss into lasting health.
Read the article here > https://kentcardio.com/latest-news/glp-1-medications-diabetes-and-weight-health-what-the-evidence-tells-us/